Akeso, Inc. 9926.HK Stock
Akeso, Inc. Price Chart
Akeso, Inc. 9926.HK Financial and Trading Overview
Akeso, Inc. stock price | 48.4 HKD |
Previous Close | 35.4 HKD |
Open | 35.95 HKD |
Bid | 37.35 HKD x N/A |
Ask | 37.45 HKD x N/A |
Day's Range | 35.45 - 37.8 HKD |
52 Week Range | 16.78 - 52.6 HKD |
Volume | 9.68M HKD |
Avg. Volume | 4.79M HKD |
Market Cap | 31.5B HKD |
Beta (5Y Monthly) | 0.498477 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 2.62 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 54.61 HKD |
9926.HK Valuation Measures
Enterprise Value | 29.27B HKD |
Trailing P/E | N/A |
Forward P/E | -25.827585 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 37.602055 |
Price/Book (mrq) | 11.949585 |
Enterprise Value/Revenue | 34.947 |
Enterprise Value/EBITDA | -20.247 |
Trading Information
Akeso, Inc. Stock Price History
Beta (5Y Monthly) | 0.498477 |
52-Week Change | 97.32% |
S&P500 52-Week Change | 20.43% |
52 Week High | 52.6 HKD |
52 Week Low | 16.78 HKD |
50-Day Moving Average | 40.11 HKD |
200-Day Moving Average | 37.11 HKD |
9926.HK Share Statistics
Avg. Volume (3 month) | 4.79M HKD |
Avg. Daily Volume (10-Days) | 3.46M HKD |
Shares Outstanding | 841.06M |
Float | 562.75M |
Short Ratio | N/A |
% Held by Insiders | 32.56% |
% Held by Institutions | 26.96% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -139.48% |
Operating Margin (ttm) | -183.55% |
Gross Margin | 87.68% |
EBITDA Margin | -172.60% |
Management Effectiveness
Return on Assets (ttm) | -18.65% |
Return on Equity (ttm) | -48.80% |
Income Statement
Revenue (ttm) | 837.66M HKD |
Revenue Per Share (ttm) | 1.02 HKD |
Quarterly Revenue Growth (yoy) | 595.20% |
Gross Profit (ttm) | 734.54M HKD |
EBITDA | -1445848960 HKD |
Net Income Avi to Common (ttm) | -1168392960 HKD |
Diluted EPS (ttm) | -1.59 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.29B HKD |
Total Cash Per Share (mrq) | 2.72 HKD |
Total Debt (mrq) | 1.88B HKD |
Total Debt/Equity (mrq) | 73.75 HKD |
Current Ratio (mrq) | 2.247 |
Book Value Per Share (mrq) | 3.134 |
Cash Flow Statement
Operating Cash Flow (ttm) | -1240413056 HKD |
Levered Free Cash Flow (ttm) | -1596709888 HKD |
Profile of Akeso, Inc.
Country | Hong Kong |
State | N/A |
City | Zhongshan |
Address | No. 6, Shennong Road |
ZIP | 528437 |
Phone | 86 76 0898 73998 |
Website | https://www.akesobio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 2341 |
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK105, a PD-1 monoclonal antibody to treat classic Hodgkin's lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals; AstraZeneca Pharmaceuticals; Summit Therapeutics Inc.; and Shenzhen Chipscreen Biosciences Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
Q&A For Akeso, Inc. Stock
What is a current 9926.HK stock price?
Akeso, Inc. 9926.HK stock price today per share is 48.4 HKD.
How to purchase Akeso, Inc. stock?
You can buy 9926.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Akeso, Inc.?
The stock symbol or ticker of Akeso, Inc. is 9926.HK.
Which industry does the Akeso, Inc. company belong to?
The Akeso, Inc. industry is Biotechnology.
How many shares does Akeso, Inc. have in circulation?
The max supply of Akeso, Inc. shares is 865.86M.
What is Akeso, Inc. Price to Earnings Ratio (PE Ratio)?
Akeso, Inc. PE Ratio is 18.47328400 now.
What was Akeso, Inc. earnings per share over the trailing 12 months (TTM)?
Akeso, Inc. EPS is 2.62 HKD over the trailing 12 months.
Which sector does the Akeso, Inc. company belong to?
The Akeso, Inc. sector is Healthcare.